Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: plasma exchange as a successful emerging therapy—case report

Malignant mesothelioma is an aggressive cancer associated with prior exposure to asbestos and dismal prognosis. Immune checkpoint inhibitor therapy is currently approved by the Food and Drug Administration for pre-treated malignant pleural mesothelioma. We describe a 75-year-old patient with dissemi...

Descripción completa

Detalles Bibliográficos
Autores principales: Schiopu, Sanziana R. I., Käsmann, Lukas, Schönermarck, Ulf, Fischereder, Michael, Grabmaier, Ulrich, Manapov, Farkhad, Rauch, Josefine, Orban, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947381/
https://www.ncbi.nlm.nih.gov/pubmed/33718042
http://dx.doi.org/10.21037/tlcr-20-1095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947381/
https://www.ncbi.nlm.nih.gov/pubmed/33718042
http://dx.doi.org/10.21037/tlcr-20-1095

Ejemplares similares